glp-1 drugs cost How much do without insurance? Employers Weighing the Obesity Drug

You are not obligated to accept one doctor assessment as final

For comorbid metabolic diseases, such as diabetes and obesity, the use of GLP-1RAs generally does not increase cancer risk and may offer certain benefits

DPP4i have a favourable therapeutic profile and are proven not to increase cardiovascular risk

As previously mentioned, patients with T2D on incretin-based therapies showed significant weight loss and improved glycemic control with little experience of hypoglycemia (47)

Table 2 Cardiovascular outcome studies with DPP-4 inhibitors

PubMed pubmed.ncbi.nlm.nih.gov [65] What is the pipeline for future medications for obesity